Imaging the Pathogenesis of Cerebral Small Vessel Disease
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorJohns Hopkins University
About this trial
Cerebral small vessel disease (CSVD) can lead to vascular cognitive impairment and dementia (VCID). The hallmark of CSVD is the appearance and progression of white matter hyperintensities (WMH) on MRI. The goal of this study it to recruit and follow individuals at risk for WMH progression and use serial MRI scanning to gain insights into the pathogenesis of CSVD.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Clinical or radiographic evidence of ischemic stroke
One vascular risk factor (hypertension, hyperlipidemia, or diabetes)
Evidence of cerebral small vessel disease on MRI
Disqualifiers
Inability to complete 3 research MRI scans over 1.25 years
Trial population
Patients who are identified as having had an ischemic stroke, have at least one vascular risk factor, have had an MRI demonstrating cerebral small vessel disease and are willing and able to come to our research facility in Baltimore for 3 MRI scans over 1.25 years.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Progression of cerebral small vessel disease
Conversion of normal appearing white matter to white matter hyperintensity measured on MRI using 3D FLAIR imaging.
Time frame
1 yearSponsors and contacts
Click on the lead sponsor to view all of their trials.
Johns Hopkins University
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
Collaborator
Source ClinicalTrials.gov